Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1095871.RASbfqbgjt6I_ZHHSju8GumvELuJBPd1_fHQ4XhEmYAc4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1095871.RASbfqbgjt6I_ZHHSju8GumvELuJBPd1_fHQ4XhEmYAc4130_assertion type Assertion NP1095871.RASbfqbgjt6I_ZHHSju8GumvELuJBPd1_fHQ4XhEmYAc4130_head.
- NP1095871.RASbfqbgjt6I_ZHHSju8GumvELuJBPd1_fHQ4XhEmYAc4130_assertion description "[Starting January 1, 2012, preemptive biomarker profiling was offered at the West German Cancer Center to all patients with advanced non-small-cell lung (NSCLC) or colorectal cancer (CRC), who met generic study inclusion criteria.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1095871.RASbfqbgjt6I_ZHHSju8GumvELuJBPd1_fHQ4XhEmYAc4130_provenance.
- NP1095871.RASbfqbgjt6I_ZHHSju8GumvELuJBPd1_fHQ4XhEmYAc4130_assertion evidence source_evidence_literature NP1095871.RASbfqbgjt6I_ZHHSju8GumvELuJBPd1_fHQ4XhEmYAc4130_provenance.
- NP1095871.RASbfqbgjt6I_ZHHSju8GumvELuJBPd1_fHQ4XhEmYAc4130_assertion SIO_000772 23876834 NP1095871.RASbfqbgjt6I_ZHHSju8GumvELuJBPd1_fHQ4XhEmYAc4130_provenance.
- NP1095871.RASbfqbgjt6I_ZHHSju8GumvELuJBPd1_fHQ4XhEmYAc4130_assertion wasDerivedFrom befree-2016 NP1095871.RASbfqbgjt6I_ZHHSju8GumvELuJBPd1_fHQ4XhEmYAc4130_provenance.
- NP1095871.RASbfqbgjt6I_ZHHSju8GumvELuJBPd1_fHQ4XhEmYAc4130_assertion wasGeneratedBy ECO_0000203 NP1095871.RASbfqbgjt6I_ZHHSju8GumvELuJBPd1_fHQ4XhEmYAc4130_provenance.